TRT Clinic
- Hyperbaric Oxygen Therapy (HBOT)
- Oxygen Therapy
- Peptide Therapy
- Erectile Dysfunction (ED) Treatment
- Testosterone Replacement Therapy (TRT)
Tempe, AZ
Tempe has an ASU-adjacent East Valley market with a young professional and athlete demographic, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across Downtown Tempe, South Tempe, and the Chandler border range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Banner Desert and Dignity Health Chandler Regional network. The scene here skews toward clinics serving university faculty, athletes, and tech workers. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Tempe clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Regulatory context
Most research peptides sold in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin are FDA-approved for specific indications. In 2023 and 2024, the FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list, which effectively restricts 503A compounding pharmacies from sourcing those ingredients. Section 503A governs traditional patient-specific compounding; Section 503B covers FDA-registered outsourcing facilities held to cGMP standards.
The Arizona State Board of Pharmacy inspects compounding facilities under USP 795 (non-sterile) and USP 797 (sterile) standards. The Board has issued disciplinary actions against pharmacies for sourcing non-compliant bulk ingredients and for sterile compounding deficiencies. Non-resident pharmacies shipping peptides into Arizona must hold a non-resident permit. Clinics sourcing from pharmacies outside the state should verify the pharmacy holds a current Arizona non-resident license.